5-Fluorouracil (5-FU) is chemotherapeutic agent widely used for the treatment of colorectal cancer. Unfortunately, advanced colorectal cancer is often resistance to such chemotherapy and poor outcome. An adaptor protein paxillin (PXN) is phosphorylated at Y31/Y118 (pPXN-Y31/Y118) by Src contributes to cell mobility and Ser (S)272 of PXN in LD4 domain is important to the interaction between PXN and Bcl-2. We thus hypothesized that pPXN-Y31/Y118 may be required for Bcl-2 protein stability via PXN interacting with Bcl-2 to confer 5-FU resistance in colorectal cancer. Mechanistically, pPXN-S272 is phosphorylated through pPXN-Y31/Y118-mediated p21 protein-activated kinase 1 (PAK1) activation and pPXN-S272 is required for PXN to interact with Bcl-2. The interaction between PXN and Bcl-2 is essential for Bcl-2 protein stability through phosphorylation of Bcl-2 at S87 (pBcl-2-S87) by pPXN-Y31/ Y118-mediated ERK activation. An increase in Bcl-2 expression by PXN is responsible for resistance to 5-FU. The resistance to 5-FU can be abolished by inhibitor of Src and PAK1 or Bcl-2 antagonist in cell and animal models. Among patients, Bcl-2 expression is positively correlated with expression of PXN and pPXN-S272, respectively. Patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors are commonly to have an unfavorable response to 5-FU-based chemotherapy, compared with patients who have high PXN, high pPXN-S272 or high Bcl-2 tumors alone. Therefore, we suggest that Src, PAK1 or Bcl-2 inhibitor may potentially overcome the resistance of 5-FU-based chemotherapy and consequently to improve outcomes in patients with PXN/Bcl-2 and pPXN-S272/Bcl-2-positive tumors. Cell Death and Differentiation (2015) 22, 779-789; doi:10.1038/cdd.2014.170; published online 17 October 2014
The incidence of colorectal cancer has markedly increased over the past two decades and became the third leading cancer death in Taiwan. 1, 2 Patients with colorectal cancer commonly receive 5-fluorouracil (5-FU)-based chemotherapy after surgical resection. 3 The 5-year survival of Dukes B patients is approximately 75%, indicating that~25% of Dukes B patients may potentially benefit from adjuvant chemotherapy. 4 However, the response rate of advancedstage patients to 5-FU-based chemotherapy was only 10-15%. 5 Therefore, there is an urgent need to establish therapeutic biomarkers and available clinical approaches to improve the response of colorectal patients who received 5-FU-based chemotherapy.
Paxillin (PXN) has been shown to promote tumor aggressiveness, including that of colorectal cancer. 6 A recent report indicated that PXN may promote cell proliferation in SW480 colon cancer cells and PXN expression was associated with overall survival (OS) but not related with Bcl-2 in colorectal cancer patients. 7 Our previous report indicated that phosphorylation of PXN at Y31/Y118 (pPXN-Y31/Y118) by Src signaling pathway increased Bcl-2 expression at a transcriptional level in lung cancer cells via ERK activation.
8 Surprisingly, our preliminary data showed that PXN-mediated Bcl-2 expression in colon cancer cells was predominately through a post-translational level, not through a transcriptional level. PXN has been reported to interact with Bcl-2 and S272 of PXN in LD4 domain is associated with PXN interaction with Bcl-2. 9 The positive feedback activation loop of phosphorylation of PXN at Ser272 (pPXN-S272) and p21 protein-activated kinase 1 (PAK1) has been shown to regulate adhesion and protrusion dynamics. 10 We thus hypothesized that Bcl-2 protein stability by PXN overexpression could have a crucial role in the resistance to 5-FU in colorectal cancer. To test the hypothesis, mechanistic studies were performed in cell and animal model to explore whether PXN-mediated Bcl-2 protein stability could confer 5-FU resistance via phosphorylation of PXN-S272 by pPXN-Y31/Y118-mediated PAK1 activation and phosphorylation of Bcl-2 at Ser87 (pBcl-2-S87) through pPXN-Y31/Y118-mediated ERK activation. Consequently, we expected that an increased Bcl-2 by PXN overexpression may be associated with unfavorable response to 5-FU-based chemotherapy in patients with colorectal cancer.
Results
The interaction between PXN and Bcl-2 increases Bcl-2 expression by protecting Bcl-2 protein degraded by proteasomes. Western blotting analysis showed that PXN and Bcl-2 were concomitantly expressed in a panel of colon cancer cell lines. Among these cells, both proteins were expressed highly in HCT116 and T84 cells, but expressed lowly in HCT15 and HT29 cells (Figure 1a) . HCT116, T84, HCT15 and HT29 cells transfected with two PXN small Figure 1 An increase in Bcl-2 protein stability by PXN overexpression in colorectal cancer cells via increased PXN interaction with Bcl-2. (a) PXN and Bcl-2 protein expression levels in a panel of colon cancer cells were determined by western blotting analysis. (b) HCT116 and T84 cells were transfected with two different PXN shRNAs. HT29 and HCT15 cells were transfected with WT PXN or mutant PXN-ΔLD4 and then these cells were treated with or without 5 μmol/l MG132 for additional 5 h. These cells lysates were immunoprecipitated with anti-PXN or-GFP-conjugated beads. Immunoprecipitates were separated by SDS-PAGE for the evaluating Bcl-2 and PXN expression by western blotting using specific antibodies. All experiments were conducted three times independently and the relative mRNA level was indicated as the fold activation relative to the control cells. The S.D. was shown by error bars. P-value was obtained from Student's t-test. (c) HCT116 cells were co-transfected with the indicated combination of WT Bcl-2 and PXN shRNA for 24 h. HT29 cells were co-transfected with the indicated combinations of WT Bcl-2, WT PXN or mutant PXN-ΔLD4 for 24 h and then these cells were incubated with cycloheximide (20 μg/ml) at the indicated time points. These treatment cells were harvested and lysed to analyze Bcl-2 levels by an anti-Flag antibody. (d) HCT116 cells were cotransfected with the indicated combinations of WT Bcl-2 and PXN shRNA for 36 h. HT29 cells were co-transfected with the indicated combinations of WT Bcl-2, WT PXN or mutant PXN-ΔLD4 for 36 h and then these cells were treated with MG132 for additional 5 h. Cell lysates were immunoprecipitated with anti-Flag-conjugated beads. Immunoprecipitates were separated by SDS-PAGE for the evaluating ubiquitin pattern by western blotting using specific antibodies. (e) HT29 cells were co-transfected with the indicated combinations of WT Bcl-2, WT PXN or mutant PXN-S272A for 36 h and then treated with MG132 for additional 5 h. Cells were lysed and the lysates were immunoprecipitated with anti-Flagconjugated beads. The HT29 cells were transfected with WT PXN or mutant PXN-S272A for 36 h and then treated with 5 μmol/l MG132 for additional 5 h. The total lysates and immunoprecipitates were separated by SDS-PAGE for the evaluating PXN, Bcl-2 and pPXN-S272 expression by western blotting using specific antibodies. (f) The PXN was overexpressed, using WT PXN or mutant PXN-Y31/118F and -S272A in HT29 cells. PXN-overexpressing HT29 cells were treated with the inhibitor of Src (0.2 μmol/l Dasatinib) or PAK1 (10 μmol/l IPA-3) for 5 h, and then these cells lysates were separated by SDS-PAGE for the evaluating PXN, Bcl-2 and pPXN-S272 expression by western blotting using specific antibodies hairpin RNAs (shRNA) and a wild-type (WT) PXN-GFP expression vector to test whether PXN expression could modulate Bcl-2 expression. As expected, PXN expression levels were decreased by PXN-knockdown in HCT116 and T84 cells and increased by PXN overexpression in HT29 and HCT15 cells (Figure 1b) . Intriguingly, Bcl-2 expression was decreased markedly in PXN-knockdown HCT116 and T84 cells compared with their parental cells with nonspecific shRNA control transfection (NC). Conversely, Bcl-2 was more significantly increased in PXN-overexpressing HT29 and HCT15 cells than their parental cells with empty vector transfection (VC). Real-time RT-PCR analysis indicated that Bcl-2 mRNA expression levels were nearly unchanged by PXN manipulation in these colon cancer cells (Figure 1b) . The change of Bcl-2 protein expression by PXN manipulation was not correspondent with Bcl-2 mRNA levels in these cells (Figure 1b) . These results suggest that the Bcl-2 protein expression modulated by PXN may be through a posttranslational level but not through a transcriptional level. As shown in Figure 1b , the decrease of Bcl-2 expression in PXN knockdown HCT116 and T84 cells was rescued by proteasomal inhibitor MG132 compared with PXN-knockdown HCT116 and T84 cells without MG132 treatment. Bcl-2 protein level decreased in HT29 and HCT15 cells with mutant PXN-ΔLD4 transfection compared with HT29 and HCT15 cells with WT PXN transfection (Figure 1b ), but Bcl-2 level in HT29 and HCT15 cells with mutant PXN-ΔLD4 transfection was nearly rescued by MG132 treatment. Immunoprecipitation (IP) assay further showed that PXN interaction with Bcl-2 was significantly decreased by PXN-knockdown in HCT116 and T84 cells, but markedly increased in WT PXNoverexpressing HT29 and HCT15 cells. However, an increase in the interaction between PXN and Bcl-2 did not observe in HT29 and HCT15 cells with mutant PXN-ΔLD4 transfection (Figure 1b) . A pulse-chase experiment using a translation inhibitor cycloheximide was performed during 0-to 9-h intervals. The half-life of Bcl-2 expression was significantly reduced in PXN-knockdown HCT116 and T84 cells and elevated in PXN-overexpressing HT29 and HCT15 cells during the time intervals compared with their parental cells ( Figure 1c and Supplementary Figure 1a) . The ubiquitination pattern of Bcl-2 protein in PXN-knockdown HCT116 and T84 cells was more extensive than in their vector control cells with MG132 treatment (Figure 1d and Supplementary Figure 1b) . The ubiquitination pattern of Bcl-2 protein in vector control and mutant PXN-ΔLD4-overexpressing HT29 and HCT115 cells was more extensive than in WT PXN-overexpressing cells with MG132 treatment (Figure 1d and Supplementary Figure 1b) . These results suggest that the elevation of Bcl-2 expression by PXN interaction with Bcl-2 may be through protecting Bcl-2 protein degradation by ubiquitin-proteasomal pathway.
Phosphorylation of PXN at S272 by PAK1 is required for PXN interaction with Bcl-2 and Bcl-2 protein stability. We examined whether pPXN-S272 could be required for PXN interaction with Bcl-2 and, in turn, increase Bcl-2 expression. HT29 and HCT15 cells were transfected with WT PXN and mutant PXN-S272A expression vector. IP analysis showed that the interaction between PXN and Bcl-2 was seen in Phosphorylation of Bcl-2 at Ser 87 (pBcl-2-S87) has an important role in Bcl-2 protein stability. 11 As shown in Figure 2a The cells lysates were separated by SDS-PAGE for the evaluating PXN, pPXN-Y31, pPXN-Y118, ERK, p-ERK and Bcl-2 expression by western blotting using specific antibodies. (c) HCT116 and PXN-overexpressing HT29 cells were treated with two kinds of ERK inhibitors (10 μmol/l U0126 or 5 μmol/l AZD6244, AZD) for 5 h. These cells were treated with or without MG132, and then cells were lysed. The cell lysates were separated by SDS-PAGE for evaluating Bcl-2 and pBcl-2-S87 expression by western blotting using specific antibodies. (d) HCT116 cells were transfected with WT Bcl-2 or mutant Bcl-2-S87A and then treated with or without 5 μmol/l AZD, for additional 5 h. HT29 cells Bcl-2 or mutant Bcl-2-S87A and then treated with or without 5 μmol/l AZD for additional 5 h. After 41 h, these cells were treated with MG132 for 5 h. Cell lysates were immunoprecipitated with anti-Flag-conjugated beads. Immunoprecipitates were separated by SDS-PAGE for evaluating ubiquitin pattern by western blotting using specific antibodies for Bcl-2 protein stability and, in turn, confers 5-FU resistance. PXN-knockdown HCT116 and PXN-overexpressing HT29 cells were further ectopically expressed and silenced Bcl-2 or direct treatment of Bcl-2 inhibitor ABT-199 to clarify whether PXN-mediated Bcl-2 could be responsible for 5-FU resistance. Bcl-2 expression was decreased and increased in PXN-knockdown HCT116 and PXN-overexpressing HT29 cells, but Bcl-2 expression was restored by Bcl-2 ectopic expression in PXN-knockdown HCT116 cells and was decreased by Bcl-2 silencing in PXN-overexpressing HT29 cells (Figure 3d upper panel) . Interestingly, the percentage of apoptotic cells induced by 5-FU treatment was rescued by ectopically expressing mimic phosphorylation of mutant Bcl-2-S87E in PXN-knockdown HCT116 cells when compared with NC cells (Figure 3d Figure 3) . 5-FU combined with oxaliplatin is frequently used for chemotherapeutics in patients with colorectal cancer. 12 The same mechanism of PXNmediated oxaliplatin resistance compared with 5-FU resistance was further evidenced in these colon cancer cells Figure 5) . In addition, Bcl-2 expression in tumors of nude mice injected with PXNoverexpressing HT29 or HCT116 cells was concomitantly decreased with phosphorylated PXN at Y118 and S272 expression (Supplementary Figure 5) . These results from the nude mice model strongly support the findings from the cell model, showing that pPXN-Y31/Y118-mediated PAK1 and ERK activation promotes Bcl-2 protein stability via phosphorylation of PXN at S272 and Bcl-2 at S87 due to increased PXN interaction with Bcl-2.
PXN, pPXN-S272 and Bcl-2 expression are associated with an unfavorable response to 5-FU-based chemotherapy in colorectal cancer patients. We expected that the coexistence of PXN or pPXN-S272 and Bcl-2 could be associated with an unfavorable response to 5-FU-based chemotherapy in colorectal cancer patients. To test the possibility, 99 patients who received 5-FU-based chemotherapy were enrolled to assess chemotherapeutic response. The representative immunostaining results of PXN, pPXN-S272 and Bcl-2 in colorectal tumors are shown in Figure 5 . Immunohistochemical data showed that high PXN and pPXN-S272 expression was seen more frequently in Duke C and Duke D tumors than in Duke A and Duke B tumors (Po0.001), but the correlation was not observed between Dukes and Bcl-2 expression (Table 1 ). In addition, PXN and (Table 1) . Patients with high PXN or with high Bcl-2 tumors were more commonly shown to have an unfavorable response to 5-FU-based chemotherapy (progressive disease, PD and stable disease, SD). Conversely, a favorable response (complete response, CR and partial response, PR) to 5-FU-based chemotherapy was a more prevalent occurrence in patients with low PXN, low pPXN-S272 or low Bcl-2 tumors (P = 0.001 for PXN; Po0.001 for Bcl-2; Table 2 ). Notably, patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors were the most common to have unfavorable responses among the four subgroups (60% versus 19% versus 11% versus 8%, Po0.001; Table 2 ). These results reveal that patients with high PXN, high pPXN-S272 or high Bcl-2 tumors may be more frequently to have unfavorable responses to 5-FU-based chemotherapy, especially in patients with high PXN/high Bcl-2 or pPXN-S272/high Bcl-2 tumors.
Discussion
Cancer death is determined by resistance to drugs and tumor relapse. Bcl-2 family proteins include Bcl-2, Bcl-xL and Mcl-1, all of which are shown to protect cell apoptosis and, in turn, enhance drug resistance.
14-17 Bcl-2 is an antiapoptotic gene involved in an evolutionarily conserved intrinsic apoptosis pathway. 18 It acts by blocking the release of cytochrome c from mitochondria and inhibiting the activation of caspase 9 and caspase 3. 18 Our data showed that Bcl-w, Mcl-1 and IAPs were not changed by PXN-knockdown and PXN overexpression in HCT116 and HT29 cells, with the exception of Bcl-xL (Supplementary Figure 6a) . However, the percentage of apoptotic cells was markedly increased by Bcl-2-knockdown in PXN-overexpressing HT29 cells, but the increase of apoptotic percentage by Bcl-xL-knockdown was relatively lower than that of Bcl-2-knockdown in PXN-overexpressing HT29 cells (Supplementary Figure 6b) These results suggest that Bcl-2 may have a more important role in PXN-mediated 5-FU resistance in colorectal cancer cells as compared with Bcl-xL.
The positive correlation of PXN with Bcl-2 expression was observed in six cell lines except DLD1 cells (Figure 1a) . K-ras and BRAF mutations were linked with activation of AKT and ERK signaling pathway. [19] [20] [21] [22] [23] [24] Therefore, the involvement of AKT and ERK activation in the increase of Bcl-2 expression can be expected in colorectal cancer. All cell lines used in this study harbored either K-ras mutation or BRAF mutation (Supplementary Figure 7a) . AKT and ERK activation were indeed observed in K-ras mutated DLD1 cells. [25] [26] [27] Our data showed that Bcl-2 expression in DLD1 cells was nearly diminished by AKT or ERK inhibitor (Supplementary Figure 7b) . Therefore, Bcl-2 expression in DLD1 cells may be through the activation of ERK and AKT signaling pathway. Bcl-2 expression was increased markedly by PXN overexpression in DLD1 cells (Supplementary Figure 7c) . Moreover, the similar mechanism of PXN-mediated Bcl-2 elevation because of increased Bcl-2 protein stability was demonstrated in PXN-overexpressing DLD1 cells (Supplementary Figure 7c) . Intriguingly, the increase of Bcl-2 by PXN overexpression because of increased protein stability was also shown in WT K-ras/BRAF SW48 cells (Supplementary Figure 7c) . Therefore, we suggest that the increased Bcl-2 expression by AKT/ERK activation is not only through K-ras/BRAF mutation but also through PXN overexpression in colon cancer cells.
The prognostic value of Bcl-2 in colorectal cancers is controversial. [28] [29] [30] [31] For example, Bcl-2 expression was associated with favorable outcome in stage II colon cancer. Some studies showed either no correlation between Bcl-2 expression and survival, or that overexpression of Bcl-2 correlated with an unfavorable outcome in colorectal cancer patients. [28] [29] [30] [31] The clinical utility is not yet verified. In this study, we provide novel evidence to demonstrate that the interaction of PXN with Bcl-2 promotes Bcl-2 protein stability via phosphorylation of PXN at S272 and Bcl-2 at S87 by pPXN-Y31/Y118-mediated PAK1 and ERK activation, and this Bcl-2 protein stability confers 5-FU resistance in cells and xenograft tumors. In the study population, patients with high PXN/high Bcl-2 or high pPXN-S272/high Bcl-2 tumors exhibited poorer outcome than those with high PXN, high pPXN-S272 or high Bcl-2 alone tumors (Supplementary Table 1) . Therefore, we suggest that PXN-mediated Bcl-2 expression may contribute to tumor malignancy and poor outcome in colorectal cancer, especially in patients receiving 5-FU-based chemotherapy.
Among patients, pPXN-S272 expression was positively correlated with PXN expression. PXN and pPXN-S272 expression were more commonly observed in late-stage tumors (Dukes C and D) than in early-stage tumors (Dukes A and B) ( Table 1 ). In addition, the highest unfavorable response rate of 5-FU-based chemotherapy and poorer outcomes were seen in patients with high PXN/ high Bcl-2 or high pPXN-S272/ high Bcl-2 tumors, who were all from Dukes C and D patients in comparison with the other three subgroups, whose tumors were only 25-73% of Dukes C and D (data not shown). To explore whether Bcl-2 protein stability through PXN interaction with Bcl-2 not only confers drug resistance but also promotes tumor malignancy, cell invasion capability was evaluated via a Matrigel Boyden chamber assay in WT PXN-overexpressing HT29 cells with or without IPA-3 treatment, and HT29 cells with mutant PXN-S272A transfection. As shown in Supplementary Figure 8 , the invasion capability was significantly suppressed by IPA-3 in WT PXN-overexpressing HT29 cells. The invasiveness was also reduced in HT29 cells with mutant PXN-S272A transfection. However, the invasion capability can be restored by MG-132 treatment in WT PXN-overexpressing HT29 cells with IPA-3 treatment and in HT29 cells with mutant PXN-S272A transfection. The change of invasion capability was consistent with Bcl-2 expression levels modulated by IPA-3 and mutant PXN-S272A in HT29 cells. These results seem to show why colorectal cancer patients with high PXN or high pPXN-S272 combined with high Bcl-2 tumors had the worst outcome as compared with patients with tumors in the other three categories. We thus suggest that Bcl-2 protein stability as a result of PXN interaction with Bcl-2 may have a crucial role in drug resistance and poor outcomes in colorectal cancer patients with Dukes C and D tumors.
In summary, we provided the evidence that Bcl-2 protein stability via PXN interaction with Bcl-2 has a crucial role in 5-FU resistance and poor outcomes in colorectal cancer. Moreover, 5-FU resistance can be conquered by Src inhibitors (Dasatinib), PAK1 inhibitors (IPA-3) or Bcl-2 antagonists (ABT-199) in cells and xenograft tumors. Therefore, we suggest that Src inhibitor or Bcl-2 antagonist may potentially conquer the resistance of 5-FU-based chemotherapy and, in turn, improve the outcome of colorectal cancer patients with high PXN/ high Bcl-2 or high pPXN-S272/high Bcl-2 tumors. Tumor response to 5-FU-based chemotherapy. Ninety-nine patients treated with 5-FU-based chemotherapy were enrolled in the study. The drug for chemotherapy is listed in Supplementary Table 3 . The treatment methods and duration of treatment was 5-FU-based therapy on day 1 every 3 weeks. The oncologists could administer the chemotherapy locally, but patients were required to return to the participating institution for evaluation after every two cycles. In the absence of PD, patients received at least four cycles of 5-FU-based chemotherapy. Colony-stimulating factors were administered at the treating physician's discretion. Dose delays and reductions were within standards for these regimens. After two and four cycles of chemotherapy, response was characterized by the four-category ordinal variables taking on the values PD, SD, PR or CR. The responses were categorized as follows: CR: a complete disappearance of all the tumors; PR: a decrease in size or number of the tumor lesions by 50% or more; PD: at least 25% increase in size or number of the tumor lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Therefore, a favorable response (CR and PR) is a decrease in tumor size of least 50% or more. Plasmid constructs and reagents. The PXN-GFP overexpression plasmid constructed into pAcGFP1-N1 vector was kindly provided by Dr. Salgia (The University of Chicago, Chicago, IL, USA). 32 Mutant PXN-GFP (tyrosine 31/118 changed to phenylalanine: Y31/118F, serine 272 changed to alanine: S272A and LD4 domain deletion: ΔLD4) and Bcl-2-Flag (serine 87 changed to alanine: S87A and serine 87 changed to glutamic acid: S87E) expression constructs containing multiple-point mutations were constructed by the QuickChange site-directed mutagenesis system (Stratagene, La Jolla, CA, USA). The Bcl-2-Flag overexpression plasmid constructed into pCMV-Tag2B vector was purchased from Addgene (Addgene Company, Cambridge, MA, USA). shBcl-2 (#1 TRCN0000040071; #2 TRCN0000010303), shBcl-XL (#1 TRCN0000033499; #2 TRCN0000033500) and shPXN (#1 TRCN0000123137; #2 TRCN0000123138) was purchased from National RNAi Core Facility, Academia Sinica, Taipei, Taiwan. Different concentrations of expression plasmids were transiently transfected into lung cancer cells (1 × 10 6 ) using the Turbofect reagent (Formentas, Glen Burnie, MD, USA). After 48 h, the cells were harvested and whole-cell extracts were assayed in subsequent experiments.
Chemicals and antibodies. Dasatinib was obtained from LC Laboratories (Woburn, MA, USA). 5-FU and IPA-3 were acquired from Sigma Chemical (St. Louis, MO, USA) unless otherwise indicated. ABT-199 was obtained from ActiveBiochem (Maplewood, NJ, USA). All other chemicals anti-cleavage caspase 3, anti-total ERK and anti-p-ERK antibodies were purchased from Cell Signaling (Danvers, MA, USA). Anti-PXN antibody was obtained from NeoMarker (Fremont, CA, USA). Anti-phosphoY31-PXN (pPXN-Y31) anti-PAK1, anti-phosphoSer144-PAK1 (p-PAK1) and anti-Bcl-2 was obtained from Genetex (Irvine, CA, USA). AntiphosphoS272-PXN (pPXN-S272) was purchased from ECM bioscience (Versailles, KY, USA). All other antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Real-time quantitative RT-PCR analysis. Total RNA extraction and reverse transcriptase reaction were described previously. 8 The following primer sequences were used for amplification of the Bcl-2 gene: the forward primer, 5′-CTGTGGATGACTGAGTACC-3′ and the reverse primer, 5′-CAGCCAGG AGAAATCAAAC-3′.
Western blotting. The cells were lysed with lysis buffer containing 0.5% NP-40, 50 mM Tris-Cl (pH 7.5), 1 mM ethylenediaminetetraacetic acid (EDTA) and protease inhibitor cocktail (Roche, Indianapolis, IN, USA). After 3 min of lysis, the cell debris was removed by centrifugation, and the protein concentration was determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and then transferred from the gel onto a polyvinylidene difluoride membrane (PerkinElmer, Norwalk, CT, USA). After blocking, the membranes were reacted with antibody at 4°C overnight, followed by incubation with horseradish peroxidase-conjugated secondary antibody for 1 h. The blots were observed using an enhanced chemiluminescence kit (PerkinElmer).
IP analysis. For the IP experiments, cells transfected with plasmids were harvested and cell lysates were prepared using IP lysis buffer (20 mmol/l Tris-Cl (pH 7.5), 150 mmol/l NaCl, 10% glycerol, and 1% Triton X-100). Cell extracts (1.5 mg) were incubated with 40 μl of anti-antibody-agarose affinity gel (Millipore, Billerica, MA, USA). After extensive washing with IP lysis buffer, the immunoprecipitated proteins were analyzed by immunoblotting using specific antibodies. 33 Immunohistochemical analysis. IHC was used to detect PXN, pPXN-S272 and Bcl-2 expression. Specimens were formalin fixed and paraffin embedded. Briefly, 3 μm sections were cut, mounted on glass and dried overnight at 37°C. All sections were then deparaffinized in xylene, rehydrated through alcohol and washed in phosphate-buffered saline. This buffer was used for all subsequent washes. Sections for PXN, pPXN-S272 and Bcl-2 detection were heated in a microwave oven twice for 5 min in citrate buffer (pH 6.0). Anti-PXN, pPXN-S272 and Bcl-2 antibody was used as the primary antibody and the incubation time was 60 min at room temperature followed by a conventional streptavidin peroxidase method (LSAB Kit K675, DAKO, Carpinteria, CA, USA). Signals were developed with 3, 3′-diaminobenzidine for 5 min and counter stained with hematoxylin. Negative controls were obtained by leaving out the primary antibody. The intensities of signals were evaluated independently by three observers. Immunostaining scores were defined as the cell staining intensity (0 = nil; 1 = weak; 2 = moderate; and 3 = strong) multiplied by the percentage of labeled cells (0-100%), leading to scores from 0 to 300. A score over 150 was rated as 'high' immunostaining, whereas a score o150 was rated as 'low'.
MTT cytotoxicity assay. The cell lines were cultured in a humidified incubator containing 95% air and 5% CO 2 at 37°C in 96-well flat-bottomed microtiter plates containing RPMI and DMEM supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 U/ml streptomycin. Before 5-FU treatment, the cells in the exponential growth phase were pretreated with overexpression and knockdown plasmids for 24 h. After 48 h of incubation, the in vitro cytotoxic effects of these treatments were determined by MTT assay (at 570 nm) and the cell viability was expressed as a percentage of the control (untreated) cells (% of control). 8 Annexin-V staining. The cells were collected by trypsinization and centrifugation at 1000 g for 5 min. Following resuspension in binding buffer (10 mM HEPES-NaOH, 140 mM NaCl, 2.5 mM CaCl 2 ) at a final cell density of 1-2 × 10 6 cells/ml, 100 μl of a single-cell suspension (1-2 × 10 5 cells) was incubated with 5 μl Annexin V-FITC and 5 μl PI for 15 min at room temperature in the dark. After the addition of 400 μl of binding buffer, the samples were analyzed using a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) within 1 h. For each sample, 10 000 events were counted. Statistical analysis. Statistical analysis was performed using the SPSS statistical software program (Version 18.0; SPSS Inc., Chicago, IL, USA). The association between tumor response and PXN protein expression was analyzed by the χ 2 test. Multivariate Cox regression analysis was performed to determine OS and relapse-free survival. The analysis was stratified for all known variables (age, gender, smoking status, tumor type and tumor stage) and protein expression.
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